The growing use of GLP-1 weight-loss drugs could significantly change how consumers buy and eat red meat, according to new analysis from the Agriculture and Horticulture Development Board.
The medications, originally developed to treat type 2 diabetes and obesity, suppress appetite and alter eating habits, leading users to consume less food overall while placing greater emphasis on protein-rich diets.
New findings from AHDB’s February 2026 YouGov tracker showed 85% of people taking GLP-1 drugs reported eating less food overall, while 43% said they were choosing more protein-dense foods such as meat and fish.
AHDB retail and consumer insight manager Vanessa Adamson said the trend pointed towards a less but better' approach to eating.
She said: “Although consumers may be buying smaller quantities, protein remains central to their diets, and research suggests many are willing to spend more on high-quality meat when they do purchase it.
“For red meat, this presents an opportunity to focus on lean, nutrient-dense cuts and premium products, such as steaks and pork tenderloins, that align with the health priorities of GLP-1 users, particularly protein for satiety and muscle maintenance.”
AHDB said international research, including a large US food demand study, suggested consumers using GLP-1 drugs were cutting overall food purchases but showing a greater willingness to pay for premium meat and seafood products.
The levy body also highlighted potential challenges for processed meat products and takeaway sectors, as users reported reducing consumption of ultra-processed and calorie-dense foods.
Retailers have already begun introducing smaller-portion, nutrient-dense meal options aimed at consumers with reduced appetites, a move AHDB said could help support future red meat consumption.
Ms Adamson added: “Red meat is well placed to remain part of a balanced diet for GLP-1 users, particularly where messaging focuses on lean cuts, quality and nutritional value.”
Share